EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Association of CD38 antigen expression with other prognostic parameters in early stages of chronic lymphocytic leukemia






Leukemia & Lymphoma 42(6): 1315-1321

Association of CD38 antigen expression with other prognostic parameters in early stages of chronic lymphocytic leukemia

The expression of the surface molecule CD38 on B cell chronic lymphocytic leukemia (B-CLL) cells has recently been described as a prognostic marker for patient survival. We have analyzed CD19/CD38 expression in 81 patients with predominantly early stages of B-CLL (69 Binet A, seven Binet B, five Binet C). Sixty-two patients (77%) had less than 30% CD38+/CD19+ cells, while 19 (23%) had > or = 30%. There was a significant association between Binet stages (A vs. B+C, p < 0.0001), Rai stages (0-II vs. III+IV, p < 0.001) and CD38 expression, confirming the published cut-off level of 30%. A particularly strong association between CD38 expression was found with soluble CD23 (sCD23) levels of > or = 2000 U/ml (p < 0.0001) and beta2-microglobulin (beta2 MG) serum levels of > or = 3 mg/l (p < 0.0001) indicating that CD38 is a marker of tumor mass as well as disease progression. A borderline association was found with lymphocyte doubling time (LDT) < 12 months (p = 0.05) due to low patient numbers, while there was no association with age, sex or immunoglobulin deficiency. Discordant results were obtained in a number of patients: 10 of 69 patients (14%) with Binet A had a CD38 > or = 30% while three of seven patients with Binet B had a CD38 < 30%. In these two subgroups CD38 and other prognostic factors gave discrepant results. Due to the early stage and short median observation time (12 months. range 1-24 months), calculations concerning patient survival were not performed. However, our data show a strong association between CD38 and other known prognostic factors. The results also suggest that this factor is not always reliable in Binet A patients.


Accession: 045319085

PMID: 11911414

DOI: 10.3109/10428190109097758



Related references

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99(3): 1023-1029, 2002

The Prognostic Significance of Combined Expression of ZAP-70 and CD38 in Chronic Lymphocytic Leukemia. Journal of the Egyptian National Cancer Institute 21(4): 287-297, 2009

The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leukemia & Lymphoma 45(3): 455-462, 2004

CD38 expression identifies two distinct prognostic subsets in B-chronic lymphocytic leukemia. Blood 96(11 Part 1): 366a-367a, November 16, 2000

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98(1): 181-186, July 1, 2001

The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia. Journal of Biological Regulators and Homeostatic Agents 18(3-4): 340-346, 2004

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6): 1840-1847, 1999

The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia. Journal of Biological Regulators and Homeostatic Agents 18(3-4): 340-346, 2005

Is assessment of surface CD38 expression worthwhile as a prognostic factor in chronic lymphocytic leukemia patients?. Hematology 13(1): 24-27, 2008

CD38 Antigen Expression and Soluble P53 Levels Predict Outcome in B-Chronic Lymphocytic Leukemia. Blood 100(11): Abstract No 2322, November 16, 2002